Invitation to Active Biotech's capital market meeting with Teva Pharmaceutical Industries in Stockholm on October 19


Welcome to Active Biotech's capital market meeting in Stockholm on October 19.
The company will, together with representatives from Teva senior management, inform on the companies' presence and activities in the multiple sclerosis (MS) market.
An update of Active Biotech's other projects will also be given.
Date: Tuesday, October 19, 2004
Time: 13:00 - 15:00
Place: IVA (The Royal Swedish Academy of Engineering Sciences), Grev Turegatan 16, Stockholm
Kindly send your notification to participate, including name, company, telephone number and e-mail address, before October 12, to Susanne Jönsson,
Fax: +46 46 19 20 50 or
Lund, September 15, 2004
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information, please contact:
Cecilia Hofvander, Manager Corporate Communication
Phone: +46 46 19 11 22 or
On June 14, 2004 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Active Biotech signed an agreement to develop and commercialise laquinimod, Active Biotech's novel immunomodulatory compound, which has the potential to be an orally available disease modifying treatment of multiple sclerosis (MS).
The agreement gives Teva the exclusive rights to develop, register, manufacture and commercialise laquinimod worldwide, with the exception of the Nordic and Baltic countries, where Active Biotech will retain all commercial rights.
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/ inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures, and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system. Copaxone®, Teva's innovative product for the treatment of Relapse Remitting Multiple Sclerosis is marketed mainly in the U.S and Europe and has market share of more than 30% in terms of prescriptions in the U.S. where it is also the second most prescribed treatment. Copaxone® is approved in 43 countries worldwide.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

pdfPress Release (PDF)